The FDA approved dapagliflozin (Farxiga) for glycemic control in children ages 10 years and older with type 2 diabetes, based on results from the phase III T2NOW trial, AstraZeneca announced. Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results